Abstracts tagged "giant cell arteritis"

Abstract Number: 0751 • ACR Convergence 2025
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Lisa Christ¹, Shalina Taylor², Yilin Xu², Rhiya Sharma², Thierry Sornasse², Yingtao Bi², Heath Guay², Arathi Setty³, Ana Romero⁴, Peter Merkel⁵, Eugenio de Miguel⁶, Christian Dejaco⁷ and Cornelia Weyand⁸, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ²AbbVie Inc, North Chicago, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie, Barcelona, Spain, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁸Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester
Background/Purpose: Interleukin-6 (IL-6) and interferon-gamma (IFNγ) have been identified as key drivers in the pathogenesis of giant cell arteritis (GCA), that promote disease progression. The…
Abstract Number: 0733 • ACR Convergence 2025
Cerebrovascular Accidents in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study
Saman Tanveer¹, Pranathi Bandarupalli², Vineeth Potluri³, Fatima Tanveer⁴ and Abdullah Saeed⁵, ¹The University of Chicago, Chicago, IL, ²Mercy St Vincent Medical Center, Toledo, OH, ³Mercy Health St. Vincent Medical Center, Toledo, OH, ⁴CMH Lahore Medical College and Institute of Dentistry, Lahore, Punjab, Pakistan, ⁵John H. Stroger Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: To assess the characteristics, interventions, and outcomes of cerebrovascular accidents (CVAs) in people with giant cell arteritis (GCA). Strokes are uncommon in this population,…
Abstract Number: 1630 • ACR Convergence 2025
Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria
Takahiko Sugihara¹, Masayoshi Harigai², Haruhito Uchida³, Yasuhiro Maejima⁴, Hajime Yoshifuji⁵, Yoshiko Watanabe⁶, Yasuhiro Onishi³, Shunsuke Furuta⁷, Tomonori Ishii⁸, Tsuyoshi Shirai⁹, Taio Naniwa¹⁰, Noriyoshi Ogawa¹¹, Yuko Kaneko¹², Hiroaki Dobashi¹³, Koichi Amano¹⁴, Jun Ishizaki¹⁵, Takako Miyamae¹⁶, Shuichi Ito¹⁷, Yoshinori Komagata¹⁸, Naoto Tamura¹⁹ and Yoshikazu Nakaoka²⁰, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, International University of Health and Welfare, Tokyo, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan, ⁵Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁶Department of General Medicine, Kawasaki Medical School, Kurashiki,, Japan, ⁷Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁸Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁹Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Nagoya City University Hospital, Nagoya, Japan, ¹¹Department of Internal Medicine ³, Hamamatsu University School of Medicine, Hamamatsu, Japan, ¹²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ¹⁴Department of rheumatology and clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ¹⁵Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ¹⁶Department of Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan, ¹⁷Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ¹⁸Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁹Juntendo University School of Medicine, Tokyo, Japan, ²⁰Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute,, Suita, Japan
Background/Purpose: Given the increasing number of patients with giant cell arteritis (GCA) in Japan and the higher incidence of Takayasu arteritis (TAK) compared to Europe…
Abstract Number: 0892 • ACR Convergence 2025
Relapse and Immune Dysregulation in Giant Cell Arteritis Are Linked to Mosaic Loss of the Y Chromosome
Simon M. Petzinna, Sophie-Marie Kirch, Maike S. Adamson, De Xi, Claus-Jürgen Bauer, Lena Kreis, Pantelis Karakostas, Rayk Behrendt, Sebastian Zimmer, Raul N. Jamin and Valentin S. Schäfer, University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Mosaic loss of the Y chromosome (mLOY) is the most common acquired somatic mutation. Epidemiological studies have linked mLOY to malignancies, as well as…
Abstract Number: 0750 • ACR Convergence 2025
Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares
Jonathan Miller¹, Sharon Cowley², Patricia Harkins³, David O'Sullivan⁴, Gearoid McGeehan⁵, Eamonn Molloy⁶, Richard Conway⁷, David Kane⁸ and Geraldine mcCarthy⁹, ¹St Vincent's University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³Trinity College Dublin, Dublin ⁸, Dublin, Ireland, ⁴Tallaght University Hospital, Dublin, Dublin, Ireland, ⁵Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, ⁶St Vincent's University Hospital, Dublin, Dublin, Ireland, ⁷Trinity College Dublin, Dublin, Dublin, Ireland, ⁸Tallaght University Hospital & Trinity College Dublin, D²⁴, Dublin, Ireland, ⁹Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the commonest idiopathic systemic vasculitis in adults over 50 years of age. It can be associated with high morbidity.…
Abstract Number: 0732 • ACR Convergence 2025
Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
marc Corbera-bellalta¹, Roser Alba-Rovira¹, Nina Visocnik¹, Farah Kamberovic¹, Ferran Araujo-Ayala¹, Georgina Espigol-Frigolé¹, Patricia Perez-Galán¹, Ken Bondensgaard², John Paolini³ and Maria Cid⁴, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Kiniksa Pharmaceuticals, Lexington, ³Kiniksa Pharmaceuticals, LEXINGTON, MA, ⁴Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Background: Giant-cell arteritis(GCA) is a chronic inflammatory disease targeting large and medium-sized arteries. Inflammation-induced vascular remodeling leads to vascular occlusion, with ischemic complications. Myofibroblasts…
Abstract Number: 1628 • ACR Convergence 2025
Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
Nuzhat Batool¹, Zuha Anwar¹, Sharika Hasan², Miltiadis Tembelis², Jason Hoffmann¹, Nihan Gencerliler², justeena Joseph³, Steven Carsons⁴ and Elise Belilos¹, ¹NYU Grossman LI School of Medicine, Queens, NY, ²NYU Grossman LI School of Medicine, Queens, ³Long Island Community Hospital, Long Island, NY, ⁴NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Advances in imaging modalities has led to increased diagnosis of aortitis. While aortitis occurring in the setting of giant cell arteritis (GCA) and Takayasu…
Abstract Number: 0891 • ACR Convergence 2025
MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.
Maxime Samson¹, Abderrahmane Bourredjem², Rodérau Outh³, Vincent Grobost⁴, François Lifermann⁵, Guillaume DIREZ⁶, Emmanuel Ribeiro⁷, Eric Oziol⁸, Valerie Devauchelle⁹, Mikael Ebbo¹⁰, Nicolas Limal¹¹, Romain Paule¹², Boris Bienvenu¹³, Antoine Poulet¹³, Sébastien Miranda¹⁴, Ygal Benhamou¹⁴, Thomas Quemeneur¹⁵, Claire Dingremont¹⁶, Andre Ramon¹⁷, Bernard Simorre⁸, Quitterie Reynaud¹⁸, Christian AGARD¹⁹, Olivier Espitia²⁰, Arsène Mekinian²¹, Jean-François Alexandra²², Emilie Berthoux²³, Laurent Perard²³, Antoine Baudet²⁴, Rafik Mesbah²⁵, David Lacôte-Delarbre²⁶, Julien Stievenart²⁷, Marc André²⁷, Jean Sébastien Allain²⁸, Rolland Jaussaud²⁹, Julie Magnant³⁰, Amélie Servettaz³¹, Hubert De Boysson³², Marc Ruivard⁴, Benjamin Terrier³³, Alexis REGENT³⁴, Amélie Cransac³⁵, Isabelle Fournel³⁶, Hervé Devilliers³⁶ and Bernard Bonnotte³⁷, ¹CHU Dijon Bourgogne, Dijon, France, ²Centre d'Investigation Clinique, CHU Dijon, Dijon, France ; INSERM, CIC ¹⁴³², Module Epidémiologie Clinique, Dijon, France, ³Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France., Clermont-Ferrand, France, ⁴Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁵Internal Medicine, CH de Dax, Dax, France, ⁶Rheumatology, CH Le Mans, Le Mans, France, ⁷Internal medicine and clinical immunology, CHU Bordeaux, Hôpital Saint-André, Bordeaux, France, ⁸Internal Medicine, CH Bézier, Bézier, France, ⁹UBO, Brest, France, ¹⁰Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹¹Internal Medicine, CHU Henri Mondor, Créteil, France, ¹²Hospital Foch, Service de medicine interne, Suresnes, Paris, Suresnes, France, ¹³Internal Medicine, Hôpital Saint Joseph, Marseille, France, ¹⁴Internal Medicine, CHU Rouen, Rouen, France, ¹⁵Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ¹⁶Internal Medicine, Groupement hospitalier Tarbes-Lourdes, Tarbes, France, ¹⁷Rheumatology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ¹⁸Internal medicine and vascular diseases, Hospices Civils de Lyon, Lyon, France, ¹⁹Internal medicine, Nantes University Hospital, Nantes, France, ²⁰CHU de Nantes, Nantes, France, ²¹Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ²²Internal Medicine, Hôpital Bichat, APHP, Paris, France, ²³Internal Medicine, Saint Luc Saint Joseph Hospital, Lyon, France, ²⁴Internal Medicine, CH Annecy, Annecy, France, ²⁵Nephrology, CH Boulogne sur Mer, Boulogne sur Mer, France, ²⁶Internal Medicine, Hôpital d’instruction des armées Saint Anne, Toulon, France, ²⁷Internal Medicine, CHU Clermont Ferrand Gabriel Montpied, Clermont Ferrand, France, ²⁸Internal Medicine and Clinical Immunology, CH Saint Malo, Saint Malo, France, ²⁹Internal Medicine and Clinical Immunology, CHU Nancy, Nancy, France, ³⁰Internal Medicine, CHU Tours, Tours, France, ³¹Internal Medicine, CHU Reims, Reims, France, ³²Internal Medicine, CHU Caean, Caen, France, ³³Cochin Hospital, Paris, France, ³⁴Hopital Cochin, Paris, France, ³⁵Pharmacy, CHU Dijon Bourgogne, Dijon, France, ³⁶Centre d'Investigation Clinique, CHU Dijon, Dijon, France ; INSERM, CIC ¹⁴³², Module Epidémiologie Clinique, Dijon, France, ³⁷Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France
Background/Purpose: This trial aimed to compare the efficacy and safety of methotrexate (MTX) vs. tocilizumab (TCZ), in combination with glucocorticoid (GC), in patients with giant…
Abstract Number: 0749 • ACR Convergence 2025
Prevalence and characteristics of subclinical Polymyalgia Rheumatica in patients with Giant Cell Arteritis
Javier Narváez¹, Paola Vidal-Montal², Martí Aguilar-Coll³, Montserrat Roig Kim⁴, Laia De Daniel Bisbe⁴, Monica Cubells⁵, Aina Fabregat⁶, Judith Palacios-Olid³, Pol Maymó-Paituvi⁴, Carmen Moragues³ and Joan Miquel Nolla⁴, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Hospital Universitari de Bellvitge, Barcelona, Spain, ⁶Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain
Background/Purpose: In clinical practice, 18F-FDG PET-CT often reveals findings suggestive of polymyalgia rheumatica (PMR) in patients with giant cell arteritis (GCA) who lack symptoms or…
Abstract Number: 0731 • ACR Convergence 2025
The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Linda Zhu¹, Arielle Mendel², Carolyn Ross³ and Jean-Paul Makhzoum¹, ¹Universite de Montreal, Montreal, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³University of Montreal, Longueuil, Canada
Background/Purpose: The objective of this systematic review is to assess the effectiveness of leflunomide in the treatment of new-onset, refractory or relapsing giant cell arteritis…
Abstract Number: 1627 • ACR Convergence 2025
A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications
Mrinalini Dey¹, Durga Prasanna Misra², Alice Bartoletti³, Georgina Ducker⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ³ASST Gaetano Pini CTO, Cremona, Italy, ⁴Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: EULAR recommendations informing the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) were previously published separately in 2015 [1] and 2020 [2]…
Abstract Number: 0776 • ACR Convergence 2025
Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial
Wolfgang Schmidt¹, Arathi Setty², Christian Dejaco³, Andrea Rubbert-Roth⁴, Maria Cid⁵, Tomonori Ishii⁶, Avani D. Joshi², Nathaniel Zerad², Aditi Kadakia⁷, Shaofei Zhao², Weihan Zhao², Ivan Lagunes², Charles Phillips⁸, Daniel Blockmans⁹ and Peter Merkel¹⁰, ¹Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ²AbbVie Inc, North Chicago, IL, ³Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁴Division of Rheumatology and Immunology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁶Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁷AbbVie Inc, Woburn, MA, ⁸AbbVie Inc, Princeton, NJ, ⁹Department of General Internal Medicine, University Hospitals Leuven; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹⁰University of Pennsylvania, Philadelphia, PA

Background/Purpose: In the SELECT-GCA phase 3 trial, treatment of patients with GCA with upadacitinib 15 mg (UPA15) demonstrated superior rates of disease remission, fewer disease…
Abstract Number: 0748 • ACR Convergence 2025
Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?
Iztok HOLC¹, Metka Koren Krajnc², Marko Gačnik³ and Anja Lah⁴, ¹University Medical Center Maribor, ²⁰⁰⁰ Maribor, Slovenia, ²University Medical center, Maribor, Slovenia, ³University Medical Center Maribor, Braslovče, Slovenia, ⁴University Medical Center Maribor, Laporje, Slovenia
Background/Purpose: Giant cell arteritis (GCA) is a chronic vasculitis where relapses frequently occur. The rates of relapses of GCA have not been defined by now.We…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
Abstract Number: 1626 • ACR Convergence 2025
A Delphi Exercise Informing the Development of Criteria to Measure Response to Treatment in Giant Cell Arteritis
Medha Soowamber¹, Milena Bond², Catalina Sanchez Alvarez³, Carol Langford⁴, Sibel Aydin⁵, FRANK BUTTGEREIT⁶, Dario Camellino⁷, Maria Cid⁸, Peter Grayson⁹, Bernhard Hellmich¹⁰, Tanaz Kermani¹¹, Nader Khalidi¹², Sarah Mackie¹³, Alfred Mahr¹⁴, Eric L Matteson³, Mehrdad Maz¹⁵, Peter Merkel¹⁶, Paul Monach¹⁷, Lorna Neill¹⁸, Cristina Ponte¹⁹, Carlo Salvarani²⁰, Wolfgang Schmidt²¹, Peter Villiger²², Kenneth Warrington²³, Christian Dejaco²⁴, Sofia Ramiro²⁵ and Zahi Touma²⁶, ¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²South Tyrol Health Trust and Teaching Hospital of the Paracelsus Medical University, Brunico, Italy, ³Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Cleveland Clinic, Moreland Hills, OH, ⁵Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany, ⁷"La Colletta" hospital, Azienda Sanitaria Locale ³ Genovese, Arenzano, Italy, ⁸Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹⁰Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ¹¹David Geffen School of Medicine, University of California, Los Angeles, CA, ¹²Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ¹³University of Leeds, Leeds, United Kingdom, ¹⁴Klinik für Rheumatologie, Kantonspital St Gallen, St Gallen, Switzerland, ¹⁵The University of Kansas Medical Center, Kansas City, KS, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷VA Boston Healthcare System, Boston, MA, ¹⁸Patient Charity Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Nethy Bridge, United Kingdom, ¹⁹Unidade Local de Saúde de Santa Maria, Lisbon, Portugal, ²⁰Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²¹Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ²²Medical Center Monbijou, Rheumatology and Clinical Immunology, Bern, Switzerland, ²³Mayo Clinic, ROCHESTER, MN, ²⁴Medical University of Graz, Graz, Austria, ²⁵Leiden University Medical Center, Bunde, Netherlands, ²⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: The therapeutic landscape of giant cell arteritis (GCA) is growing rapidly but there are currently no internationally standardized criteria for assessing response to treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].